OxThera raises EUR 32 million to complete development of Oxabact® for treatment of Primary hyperoxaluria

by Ysios Capital

The investment round is co-led by Life Sciences Partners, Netherlands, Ysios Capital, Spain, Sunstone Capital, Denmark, and Flerie Invest, Sweden, in addition to current shareholders Kurma Partners, F...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Abierta la convocatoria para Decelera Me...

by Sancus Capital

Desde su fundación en 2015, Decelera ha revolucionado el ecosistema e...

Photos Stream